A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

Andrew Webb, David Cunningham, J.H. Scarffe et al. · Journal of Clinical Oncology · 1997 · 873 citations

Medicine, Oncology, Pharmacology +15

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 824 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

Yuh Sakata, Atsushi Ohtsu, N Horikoshi et al. · European Journal of Cancer · 1998 · 564 citations

Medicine, Oncology, Pharmacology +11

Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group

U. Vanhoefer, Philippe Rougier, H. Wilke et al. · Journal of Clinical Oncology · 2000 · 533 citations

Medicine, Oncology, Pharmacology +16